Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome

Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome

(2015) Susanne Tan et al.   International Journal of Endocrinology

In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls

(2014) Frangiskos Economou et al.   Hormones-International Journal of Endocrinology and Metabolism

Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome

(2014) G. Targher et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls

(2014) Justyna Kuliczkowska Plaksej et al.   International Journal of Endocrinology

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease

(2013) H. Kahal et al.   CLINICAL ENDOCRINOLOGY

Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents Metformin and its clinical use: new insights for an old drug in clinical practice

(2012) Arrigo F.G. Cicero et al.   Archives of Medical Science

Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options

(2012) Konstantinos Tziomalos et al.   Current Vascular Pharmacology

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Polycystic Ovary Syndrome with Hyperandrogenism Is Characterized by an Increased Risk of Hepatic Steatosis Compared to Nonhyperandrogenic PCOS Phenotypes and Healthy Controls, Independent of Obesity and Insulin Resistance

(2012) Helen Jones et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The diagnosis of non-alcoholic fatty liver disease

(2011) N. Wlazlo et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome

(2011) Maria F. Gangale et al.   CLINICAL ENDOCRINOLOGY

Fatty liver index in polycystic ovary syndrome

(2011) Elisabeth Lerchbaum et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study

(2011) D. Panidis et al.   HUMAN REPRODUCTION

The Lipid Accumulation Product Is Associated with Impaired Glucose Tolerance in PCOS Women

(2011) Elisabeth Wehr et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Polycystic ovary syndrome: etiology, pathogenesis and diagnosis

(2011) Mark O. Goodarzi et al.   Nature Reviews Endocrinology

A simple index of lipid overaccumulation is a good marker of liver steatosis

(2010) Giorgio Bedogni et al.   BMC GASTROENTEROLOGY

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies

(2010) Robert P. Myers et al.   LIVER INTERNATIONAL

Alanine Aminotransferase,  -Glutamyltransferase, and Incident Diabetes: The British Women's Heart and Health Study and meta-analysis

(2009) A. Fraser et al.   DIABETES CARE

Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome

(2009) Athina Markou et al.   FERTILITY AND STERILITY

Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors

(2009) Anna Kotronen et al.   GASTROENTEROLOGY

Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Do androgens play a role?

(2009) Robert P. Kauffman et al.   GYNECOLOGICAL ENDOCRINOLOGY

Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation

(2009) Giovanni Musso et al.   HEPATOLOGY

Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome

(2009) E. Vassilatou et al.   HUMAN REPRODUCTION

Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome

(2009) D. Wiltgen et al.   HUMAN REPRODUCTION

Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy

(2009) Andrea J. Cussons et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Apoptotic Markers Indicate Nonalcoholic Steatohepatitis in Polycystic Ovary Syndrome

(2009) Susanne Tan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study

(2009) Srinivasan Dasarathy et al.   JOURNAL OF HEPATOLOGY

The Lipid Accumulation Product and All-cause Mortality in Patients at High Cardiovascular Risk: A PreCIS Database Study

(2009) Adriana G. Ioachimescu et al.   Obesity

Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria

(2008) A.J. Goverde et al.   HUMAN REPRODUCTION

The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome

(2008) D. Preiss et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Withdrawn: Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation

(2008) Leslee J. Shaw et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM